Hal Hirte

A Phase I Study of OGX-011, a 2′-Methoxyethyl Phosphorothioate Antisense to Clusterin, in Combination with Docetaxel in Patients with Advanced Cancer

Kim N., Lillian L. Siu, Hal Hirte et al. · Clinical Cancer Research · 2008 · 119 citations · Full text

Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial

Agustin A. García, Amit M. Oza, Hal Hirte et al. · Journal of Clinical Oncology · 2005 · 65 citations

Recurrent Ovarian, Immunology, Gynecology +21

Two Phase I Studies of Carboplatin Dose Escalation in Chemotherapy-Naive Ovarian Cancer Patients Supported With Patients Supported With Granulocyte-Macrophage Colony-Stimulating Factor

James J. Rusthoven, Leslie Levin, E. Eisenhauer et al. · JNCI Journal of the National Cancer Institute · 1991 · 29 citations

An international multicentre Phase III study of BAY 12-9566 (BAY) versus placebo in patients (pts) with advanced ovarian cancer (OVCA) responsive to primary surgery/Paclitaxel + Platinum containing chemotherapy (CT)

Hal Hirte, Ignace Vergote, J Jeffrey et al. · 2001 · 17 citations

Advanced Ovarian Cancer, Medicine, Metronomic Therapy +8

Phase I Clinical Trial of Recombinant Human Interleukin-3 Combined With Carboplatin in the Treatment of Patients With Recurrent Ovarian Carcinoma

James J. Rusthoven, E. Eisenhauer, J. Mazurka et al. · JNCI Journal of the National Cancer Institute · 1993 · 13 citations

Medicine, Immunology, Recurrent Ovarian Carcinoma +6